Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

Malignant Solid Neoplasm Clinical Trial

Official title:

Topical Cannabidiol (CBD) for the Treatment of Chemotherapy-Induced Peripheral Neuropathy: A Randomized Placebo-Controlled Pilot Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05388058
• Other study ID #: MC211003
• Secondary ID: NCI-2022-0247921
• Status: Completed
• Phase: Phase 2
• Start date: June 9, 2022
• Est. completion date: July 28, 2023

Study information

• Verified date: April 2024
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial compares topical cannabidiol to placebo in improving chemotherapy-induced peripheral neuropathy, or painful sensations in your hands or feet due to chemotherapy. Peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. It usually begins in the hands or feet and gets worse over time. Peripheral neuropathy caused by chemotherapy is called chemotherapy-induced peripheral neuropathy (CIPN). CIPN is commonly seen in patients receiving certain chemotherapy medications and is hard to treat. Medications commonly used to treat CIPN have limited benefits and may cause significant side effects. A small report showed that topical cannabidiol may help treat neuropathy in patients with diabetes. This study is being done to determine if cannabidiol cream can help improve the symptoms of CIPN.

Description:

PRIMARY OBJECTIVES:

I. To evaluate whether topical cannabidiol (CBD) improves CIPN, compared to placebo.

II. To evaluate side effects from topical CBD cream use, compared to placebo.

SECONDARY OBJECTIVES:

I. Other measures of neuropathy as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) CIPN20 motor subscale, the EORTC QLQ CIPN20 autonomic scale, and the total Common Terminology Criteria for Adverse Events (CTCAE) neuropathy scale.

II. Adverse event profiles will also be assessed using symptom questionnaires and CTCAE version (v)5.0.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients apply cannabidiol cream topically to affected areas twice daily (BID) for 14 days. Patients then apply placebo cream topically to affected areas BID for 14 days.

ARM II: Patients apply placebo cream topically to affected areas BID for 14 days. Patients then apply cannabidiol cream topically to affected areas BID for 14 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: July 28, 2023
• Est. primary completion date: July 14, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >= 18 years

• English speaking

• Cancer diagnosis of any tumor type with chemotherapy-induced neuropathy

• At least 4 out of 10 severity of neuropathy pain and/or tingling

• Stable for at least 7 days prior to registration on medications for neuropathy, if any are being used

• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

• Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only

• NOTE: If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required

• Able to provide written informed consent

• Ability to complete questionnaire(s) by themselves or with assistance

• No evidence of residual cancer

• Platelet count > 100,000/mm^3 (following completion of chemotherapy)

• Absolute neutrophil count (ANC) >= 1,000/mm^3 (following completion of chemotherapy)

• Hemoglobin > 11 g/dL (following completion of chemotherapy)

• Serum transaminase (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) =< 1.2 x upper limit of normal (ULN) (following completion of chemotherapy)

• Alkaline phosphatase =< 1.2 x ULN (following completion of chemotherapy)

• Serum creatinine =< 1.2 x ULN (following completion of chemotherapy)

Exclusion Criteria:

• Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:

• Pregnant persons

• Nursing persons

• Persons of childbearing potential who are unwilling to employ adequate contraception

• Any medical condition that would prohibit use of a topical cream (skin infection or open wound in the area of the neuropathy)

• Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

• Pre-existing neuropathy prior to chemotherapy that would confuse the issue of CIPN

• Currently on chemotherapy or received chemotherapy treatment within the prior 3 months

• Use of other cannabis products within 30 days prior to registration

• History of allergy to cannabis products

Related Conditions & MeSH terms

• Chemotherapy-Induced Peripheral Neuropathy
• Malignant Solid Neoplasm
• Peripheral Nervous System Diseases

Intervention

Drug:
• Cannabidiol
Applied topically
• Placebo Administration
Applied topically

Other:
• Quality-of-Life Assessment
Ancillary studies
• Questionnaire Administration
Ancillary studies

Locations

Country	Name	City	State
United States	Mayo Clinic Health System Albert Lea	Albert Lea	Minnesota
United States	Fairview Grand Itasca Clinic and Hospital	Grand Rapids	Minnesota
United States	Fairview Range Medical Center	Hibbing	Minnesota
United States	Mayo Clinic Health System Mankato	Mankato	Minnesota
United States	Monticello Cancer Center	Monticello	Minnesota
United States	Fairview Northland Medical Center	Princeton	Minnesota
United States	Mayo Clinic in Rochester	Rochester	Minnesota
United States	Sanford Thief River Falls	Thief River Falls	Minnesota
United States	Sanford Worthington	Worthington	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in chemotherapy-induced peripheral neuropathy (CIPN)	CIPN will be measured by the sensory subscale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-CIPN20 which is composed of 9 individual items. Will be compared between arms using two-sample, two-sided t-tests. The cannabidiol arm will be compared to the placebo arm. Will construct 95% confidence intervals for the mean difference in sensory neuropathy score between arms. Repeated measures mixed models will be applied to the sensory scores over all time points to determine longitudinal effects and to adjust for confounding factors. Graphical results will include profile plots over time, stream plots of individual changes over time, and forest plots of the 95% confidence intervals by arm.	Baseline to end of week 2
Secondary	Change in EORTC QLQ CIPN20 motor subscale	Will be compared between arms using two-sample, two-sided t-tests. The cannabidiol arm will be compared to the placebo arm. Will construct 95% confidence intervals for the mean difference in sensory neuropathy score between arms. Repeated measures mixed models will be applied to the sensory scores over all time points to determine longitudinal effects and to adjust for confounding factors. Graphical results will include profile plots over time, stream plots of individual changes over time, and forest plots of the 95% confidence intervals by arm.	Baseline to end of week 2
Secondary	Change in EORTC QLQ CIPN20 autonomic scale	Will be compared between arms using two-sample, two-sided t-tests. The cannabidiol arm will be compared to the placebo arm. Will construct 95% confidence intervals for the mean difference in sensory neuropathy score between arms. Repeated measures mixed models will be applied to the sensory scores over all time points to determine longitudinal effects and to adjust for confounding factors. Graphical results will include profile plots over time, stream plots of individual changes over time, and forest plots of the 95% confidence intervals by arm.	Baseline to end of week 2
Secondary	Total Common Terminology Criteria for Adverse Events (CTCAE) neuropathy scale	Will compare the incidence and maximum (worst) values between arms. Fisher's exact tests will be used to compare incidence rates and Wilcoxon rank-sum tests will be used to compare maximum values between arms.	Up to 14 days
Secondary	Incidence of adverse events	Will be assessed using symptom questionnaires and CTCAE version 5.0. Will compare the incidence and maximum (worst) values between arms. Fisher's exact tests will be used to compare incidence rates and Wilcoxon rank-sum tests will be used to compare maximum values between arms.	Up to 28 days